4D Molecular Therapeutics Inc
NASDAQ:FDMT
Income Statement
Earnings Waterfall
4D Molecular Therapeutics Inc
Income Statement
4D Molecular Therapeutics Inc
| Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||
| Revenue |
1
N/A
|
16
+1 429%
|
17
+9%
|
18
+6%
|
17
-4%
|
3
-84%
|
2
-31%
|
3
+59%
|
2
-29%
|
2
+4%
|
22
+860%
|
21
-6%
|
41
+99%
|
41
-1%
|
21
-49%
|
0
-100%
|
0
-38%
|
0
+43%
|
0
+264%
|
|
| Operating Income | ||||||||||||||||||||
| Operating Expenses |
(38)
|
(60)
|
(84)
|
(89)
|
(99)
|
(105)
|
(108)
|
(113)
|
(116)
|
(120)
|
(127)
|
(134)
|
(238)
|
(248)
|
(265)
|
(188)
|
(203)
|
(220)
|
(230)
|
|
| Selling, General & Administrative |
(12)
|
(19)
|
(28)
|
(28)
|
(31)
|
(32)
|
(32)
|
(33)
|
(33)
|
(33)
|
(34)
|
(36)
|
(65)
|
(66)
|
(70)
|
(47)
|
(49)
|
(50)
|
(49)
|
|
| Research & Development |
(25)
|
(41)
|
(56)
|
(61)
|
(68)
|
(73)
|
(76)
|
(80)
|
(83)
|
(86)
|
(93)
|
(97)
|
(174)
|
(182)
|
(195)
|
(141)
|
(154)
|
(170)
|
(181)
|
|
| Operating Income |
(37)
N/A
|
(44)
-21%
|
(67)
-51%
|
(71)
-6%
|
(81)
-14%
|
(102)
-26%
|
(106)
-4%
|
(110)
-4%
|
(114)
-3%
|
(117)
-3%
|
(105)
+11%
|
(113)
-8%
|
(197)
-75%
|
(207)
-5%
|
(245)
-18%
|
(188)
+23%
|
(203)
-8%
|
(220)
-8%
|
(230)
-5%
|
|
| Pre-Tax Income | ||||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
3
|
4
|
6
|
9
|
12
|
24
|
29
|
33
|
27
|
27
|
24
|
21
|
|
| Total Other Income |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
|
| Pre-Tax Income |
(37)
N/A
|
(45)
-21%
|
(67)
-50%
|
(71)
-7%
|
(81)
-14%
|
(102)
-25%
|
(105)
-3%
|
(107)
-2%
|
(110)
-2%
|
(111)
-1%
|
(96)
+14%
|
(101)
-5%
|
(173)
-72%
|
(178)
-3%
|
(212)
-19%
|
(161)
+24%
|
(176)
-10%
|
(196)
-11%
|
(209)
-7%
|
|
| Net Income | ||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(37)
|
(45)
|
(67)
|
(71)
|
(81)
|
(102)
|
(105)
|
(107)
|
(110)
|
(111)
|
(96)
|
(101)
|
(173)
|
(178)
|
(212)
|
(161)
|
(176)
|
(196)
|
(209)
|
|
| Net Income (Common) |
(37)
N/A
|
(45)
-21%
|
(67)
-50%
|
(71)
-7%
|
(81)
-14%
|
(102)
-25%
|
(105)
-3%
|
(107)
-2%
|
(110)
-2%
|
(111)
-1%
|
(96)
+14%
|
(101)
-5%
|
(173)
-72%
|
(178)
-3%
|
(212)
-19%
|
(161)
+24%
|
(176)
-10%
|
(196)
-11%
|
(209)
-7%
|
|
| EPS (Diluted) |
-1.38
N/A
|
-1.66
-20%
|
-2.47
-49%
|
-2.57
-4%
|
-2.52
+2%
|
-3.14
-25%
|
-3.24
-3%
|
-3.32
-2%
|
-3.35
-1%
|
-2.9
+13%
|
-2.27
+22%
|
-2.58
-14%
|
-3.51
-36%
|
-3.22
+8%
|
-3.81
-18%
|
-2.98
+22%
|
-3.17
-6%
|
-3.52
-11%
|
-3.74
-6%
|
|